Moore Threads-U shares rose over 10% intraday, returning the price to 400 yuan.

China has approved 59 innovative drugs year-to-date, including 13 with novel mechanisms or targets, signaling steady gains in original innovation capacity. From January–August there were 113 biopharma business-development deals nationwide totaling $119.997 billion; Shanghai led with 37 deals, or 33% of the national total. Shanghai’s biopharma sector reached 500.566 billion yuan in 1H2025 and is forecast to exceed 1 trillion yuan in 2026, becoming the city’s fifth trillion-yuan industry cluster.

US building permits, August: 1.394 mln units vs. consensus 1.41 mln; prior 1.433 mln.